InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. Lake Street Capital initiated coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Down 6.3 %

Shares of NYSE NSPR opened at $2.69 on Friday. The stock’s 50 day moving average price is $2.73 and its two-hundred day moving average price is $2.70. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42. The stock has a market capitalization of $70.17 million, a P/E ratio of -3.59 and a beta of 0.98.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same period in the prior year, the company posted ($0.15) EPS. On average, analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD at the end of the most recent quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.